News|Articles|November 20, 2026

Health Equity & Access Weekly Roundup: November 20, 2026

Fact checked by: Laura Joszt, MA
Listen
0:00 / 0:00

Key Takeaways

  • Employer diabetes strategies should validate benefit design, amplify NDPP and DSMES access, and operationalize a multi-tier model where GLP-1 agents complement prevention, education, and accommodations.
  • Camden residents requested psychedelic therapy pathways grounded in lived experience, trained facilitators, transparent evidence, and equitable coverage with enabling services; New Jersey pilots may include a Medicaid-focused model.
SHOW MORE

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

New Employer Guide Maps Diabetes Prevention, Care Resources

The Greater Philadelphia Business Coalition on Health (GPBCH) released its 2026 Diabetes Resource Guide in September as a reference for employers on diabetes prevention and management. Elzbieta Dziekonski, RN, GPBCH's director of Population Health Initiatives, said offering a benefit does not ensure employees know it exists, and she urged employers to confirm coverage and communicate year-round about the National Diabetes Prevention Program and Diabetes Self-Management Education and Support.

The guide estimates that a 1000-employee company would include 116 workers with diabetes and 350 with prediabetes, and it cites a national cost of $412.9 billion for diagnosed diabetes in 2022. Its 4-tier framework positions glucagon-like peptide-1 receptor agonists as one part of a broader plan, and it also outlines workplace accommodations.

Camden Residents Weigh In on Psychedelic Therapy: Jeff Brown

Jeff Brown, president and chief strategy officer at the Camden Coalition, said a community-driven rollout of psychedelic-assisted therapy should begin with listening to residents. At a September town hall in Camden, New Jersey, residents were divided, with some supportive and others questioning the research and efficacy. Participants asked for care models that honor spirituality, culture, and lived experience; equitable access across Medicaid, Medicare, and commercial insurance; and supports such as transportation, child care, and language access. They also requested plain-language evidence, trained facilitators, and community input in site selection. Brown said New Jersey is setting up 3 state-funded research pilots, and the coalition hopes its engagement work will inform pilot development, particularly a Medicaid-focused pilot.

Low CRC Incidence Found After Endoscopic Mucosal Resection

A study in the Journal of Gastrointestinal Cancer used the TriNetX US Collaborative Network to follow 3081 patients who underwent endoscopic mucosal resection (EMR) between 2016 and 2017. Over 10,187.8 person-years, 22 patients received a colorectal cancer (CRC) diagnosis, an incidence of 2.16 per 1000 person-years (95% CI, 1.35-3.27), and an analysis limited to patients aged 50 to 75 years produced a nearly identical estimate. The point estimate was higher among Black, Asian, and unknown-race patients combined than among White patients (3.16 vs 1.94 per 1000 person-years), but it rested on only 7 events, and CIs overlapped. The authors said missing data on surveillance adherence and insurance continuity limited conclusions about equitable surveillance.

Urban Hospital Care Linked to Better HFrEF Outcomes for Rural Patients

A JAMA Cardiology study of 735,460 Medicare fee-for-service beneficiaries hospitalized for heart failure with reduced ejection fraction (HFrEF) from 2013 to 2021 examined how patient and hospital rurality shape care. Rural patients treated at urban hospitals had about twice the odds of an inpatient cardiology consultation (OR, 2.02; 95% CI, 1.84-2.22) and lower 90-day mortality (OR, 0.94; 95% CI, 0.91-0.97) than rural patients treated at rural hospitals. Even so, they had higher 30-day mortality (OR, 1.10; 95% CI, 1.06-1.14) than urban patients treated at the same hospitals, with no significant difference at 1 year. The authors cited delayed follow-up, social determinants of health, and medication affordability as possible contributors and pointed to transitional care and telehealth follow-up.

GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says

A report from the JAMA Summit on Obesity, published in JAMA, concluded that effective obesity medications offer a major opportunity but cannot reverse an epidemic rooted in structural and environmental drivers. The authors estimated that 1 in 9 US adults currently takes a glucagon-like peptide-1 receptor agonist and said obesity prevalence may be declining for the first time in decades, while severe obesity continues to rise. They said the insurance system discourages treatment through noncoverage and onerous prior authorizations, and they called for coverage of lifestyle, medical, and surgical care, stronger regulation of compounded drugs, food policy action, and stigma-free care environments. The report suggested expanding the Medicare GLP-1 Bridge and the Medicaid BALANCE initiative if they prove successful.


Related to this article